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Abstract
Background: Human T-lymphotropic virus type 1 (HTLV-1) is the etiologic agent of a severe and
fatal lymphoproliferative disease of mainly CD4+ T cell origin, adult T cell leukemia, which develops
after prolonged viral persistence. Transformation of infected cells involves HTLV-1's oncoprotein
Tax, which perturbs cell cycle regulation and modulates cellular gene expression. The latter
function is also a hallmark of microRNAs, a rather new layer in the regulation of gene expression.
Affecting e.g. proliferation, microRNAs constitute a potential target for viral interference on the
way to persistence and transformation. Hence, we explored the interconnections between HTLV-
1 and cellular microRNAs.
Results: We report that several microRNAs – miRs 21, 24, 146a, 155 and 223 – are deregulated
in HTLV-1-transformed cells. They are all upregulated except for miR-223, which is downregulated.
Each of those microRNAs has ties to cancer. Their expression pattern forms a uniform phenotype
among HTLV-transformed cells when compared to HTLV-negative control cells. In particular, miR-
146a expression was found to be directly stimulated by Tax via NF-κB-mediated transactivation of
its promoter; a single NF-κB site proximal to the transcription start point was necessary and
sufficient for this to happen. An in silico analysis of potential target genes revealed candidates that
might be coregulated by two or more of the aforementioned overexpressed microRNAs.
Conclusion:  These data demonstrate that cellular microRNAs are deregulated in HTLV-1-
transformed T cells. In the case of miR-146a, this could be directly attributed to HTLV's
oncoprotein Tax. Interference with cellular microRNAs may be crucial to maintaining persistence
or may facilitate transformation of host cells.
Background
Human T-lymphotropic virus type 1 (HTLV-1) is a δ-retro-
virus infecting primarily CD4+ T lymphocytes in vivo. Life-
long persistence ensues, which, after decades, can entail
an aggressive neoplastic disease, adult T cell leukemia/
lymphoma (ATLL). Another HTLV-1-associated disease
presents as progressive neurodegeneration termed HTLV-
associated myelopathy/tropical spastic paraparesis
(HAM/TSP) [1-4]. HTLV's persistence manifests itself in T
cell clones which remain detectable over many years even
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in non-leukemic infected individuals [5,6]. In the face of
a continuous immune response this requires constant
replenishment of infected cells. The virus achieves this
through replication mainly in its provirus form, stimula-
tion of cell division and, as a consequence, clonal ampli-
fication of infected cells.
HTLV-1 encodes accessory and regulatory proteins. While
the accessory ones, p12, p30, p13 [7,8] and HBZ [9], are
important for infectivity and viral replication [7,10], they
are dispensable for immortalization [11-13]. The regula-
tory protein Tax drives viral mRNA synthesis by transacti-
vating the HTLV-1 long terminal repeat promoter, Rex
controls the synthesis of the structural proteins on a post-
transcriptional level [14,15]. Both of them are essential
for viral replication.
Tax confers the transforming properties on HTLV-1 [16].
It can immortalize T lymphocytes [17,18] and induce
leukemia in transgenic mice [19]. Biochemically, several
Tax functions, including transcriptional dysregulation
and interference with cell cycle checkpoints, may contrib-
ute to its transforming capacity; they have been reviewed
elsewhere [16]. For example, Tax is able to stimulate tran-
scription by interacting with various signalling pathways.
It activates both the canonical and the non-canonical
pathways of nuclear factor kappa B (NF-κB), the former by
binding and stimulating IKKγ, a component of the inhib-
itor of kappa B kinase (IKK) complex [10]. Apart from NF-
κB, Tax is also capable of transactivating cellular promot-
ers via direct contact with transcriptional activators CREB
and SRF and with the coactivators p300/CBP [20,21].
Several publications describe phenotypical parallels
between HTLV-transformed cells and regulatory T cells.
These parallels comprise expression of markers like CD4,
CD25, GITR [22] and FoxP3 [23,24]. However, it is still
being disputed whether HTLV-transformed cells exhibit a
distinct suppressive property [25,26]. When comparing
HTLV-transformed cells with uninfected ones, looking at
a phenotypically close population, i.e., one carrying the
abovementioned markers, may help to obtain meaningful
results. For this reason, we choose the phenotype of regu-
latory T cells as a starting point for our investigations into
microRNA expression.
MicroRNAs have surfaced as being posttranscriptional
regulators of gene expression [27]. The genes encoding
them are transcribed by RNA polymerase II producing pri-
mary transcripts (pri-miR) which feature a stem-loop
structure that is excised by an RNase, Drosha. The result-
ing hairpin is exported to the cytoplasm where another
RNase, Dicer, converts it to the mature single-stranded
microRNA [28]. The about 23 nucleotides long RNA mol-
ecules exert their function by binding to the 3' untrans-
lated regions (3'-UTRs) of target mRNAs thus guiding a
protein machinery, the microRNA-induced silencing
complex (miRISC), which then suppresses translation of
the mRNA. For in-depth reviews of microRNA function in
lymphocytes see [29] and, with emphasis on microRNAs
in virus infections, [30,31]. Cellular functions that micro-
RNAs influence include lymphocyte differentiation
[32,33], and some have even been implicated in oncogen-
esis [34,35].
To identify microRNAs involved in the pathogenesis of
HTLV-associated disease, we selected a microRNA subset
both characteristic of murine regulatory T cells (Treg) and
reported to be deregulated in tumors. Within that subset,
a single microRNA was downregulated and four microR-
NAs were overexpressed in HTLV-/Tax-transformed cell
lines. Subsequent analysis established that one, miR-
146a, was transactivated by Tax via promoter activation
mediated by NF-κB. Using online databases that catalogue
predicted microRNA target genes we looked for instances
of possible functional cooperation between the four over-
expressed microRNAs.
Results
A text-mining approach identifies seven candidate 
microRNAs with potential for a part in HTLV pathogenesis
Since microRNAs affect cellular proliferation, differentia-
tion and, ultimately, can play a part in tumorigenesis, we
investigated their role in HTLV pathogenesis. Until now,
no microRNAs encoded by HTLV-1 have been found
although regulatory functions of non-coding HTLV-RNA
have been described [36]. Consequently, using cellular
microRNAs constitutes the only way for the virus to access
that layer of regulation of gene expression. We chose a
text-mining approach to narrow down the number of can-
didate microRNAs. This employed a set of two filters, first,
one looking specifically at microRNAs expressed in natu-
rally occurring T cell populations that exhibit closest sim-
ilarity to cells transformed by HTLV and, second, another
one selecting microRNAs – out of those returned by the
first filter – with a documented link to oncogenesis.
Data suggest that regulatory T cells are the nearest pheno-
typical neighbour to CD4+ T cells transformed by HTLV.
The set of markers described for Treg comprises CD4,
CD25, GITR, FoxP3 and 4-1BB, all of which have been
found in HTLV-infected and/or -transformed cells [22-
24,37]. FACS analyses confirmed this phenotype for the
HTLV cell lines we used (data not shown). Cobb and col-
leagues compared microRNA expression patterns of regu-
latory and normal CD4+  T cells, the latter with and
without stimulation, in mice [38]. About 20 microRNAs
were exclusively expressed or upregulated in Treg, out of
those, seven had a published link to cancer: mir-21, miR-
24, miR-146a, miR-155, miR-191, miR-214 and miR-223Retrovirology 2008, 5:100 http://www.retrovirology.com/content/5/1/100
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[39]. All are described as being overexpressed in solid
tumors or lymphoproliferative disease [39-41]; some have
even been ascribed the potential to cause cancer [42].
Consequently, these microRNAs may contribute to trans-
formation of HTLV-1-infected cells, i.e., the pathogenesis
of ATLL, by either maintaining differentiation status or
actively driving cells towards a transformed state.
Upregulation of the BIC oncogene in HTLV-1-transformed 
lymphocytes can be seen on primary transcript level
Being the most prominent oncomiR, miR155, which is
encoded by the BIC gene, was analyzed first. Originally,
BIC was identified as an avian leukosis virus insertion site
in B cell lymphomas of chicken [43] and, since then, has
been verified as an oncogene in several experimental sys-
tems including transgenic mice [44]. The primary tran-
script, pri-miR-155, is generated by RNA polymerase II
and processed to mature miR-155 afterwards. Its upregu-
lated expression is also linked to human lymphoprolifer-
ative diseases like chronic lymphocytic leukemia, diffuse
large B cell lymphoma and some forms of Burkitt's lym-
phoma [40,45,46].
To test whether elevated levels of BIC primary transcripts
are a consistent feature of HTLV-infected cells RT-PCR was
performed (Fig. 1A). RNA was isolated from cultures
derived from ATLL patients (HuT-102, StEd, ATL3, PaBe,
JuanaW), from HAM/TSP patients (Abgho, Eva, Nilu,
Xpos) and from HTLV-1 and Tax in vitro-transformed cells
(MT-2, C91-PL and Tesi, respectively). CD4+ acute lym-
phoblastic leukemia (ALL) T cell lines, primary PBMC,
and CD4+ T cells from healthy donors served as HTLV-
negative controls. HTLV-transformed cells uniformly
expressed pri-miR-155 whereas it remained undetectable
in other CD4+ T cell leukemic cell lines (HuT-78, Jurkat,
Molt4) (Fig. 1A). These results were in line with microar-
Pre-miR-155 is uniformly expressed in HTLV-transformed lymphocytes Figure 1
Pre-miR-155 is uniformly expressed in HTLV-transformed lymphocytes. (A) The primary transcript of the BIC gene, 
pri-miR-155, and β-actin (ACTB) mRNA were detected by RT-PCR. (B) Pri-miR-155 abundance was determined by qPCR. Rel-
ative copy number was computed by normalizing the pri-miR-155 transcripts to those of ACTB. Values of two independent 
measurements are shown.
pri-miR-155
β-actin
Jurkat
HuT-78
Molt4
Tesi
Tesi Tet
PBMC
CD4 +
MT-2
C91-PL
HuT-102
StEd
ATL3
PaBe
JuanaW
Abgho
Eva
Nilu
Xpos
water A
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
0.2
Jurkat
HuT-78
Molt4
Tesi
TesiTet
PBMC
CD4
+
MT-2
C91-PL
HuT-102
StEd
ATL3
PaBe
JuanaW
Abgho
Eva
Nilu
Xpos
B
I
C
/
p
r
i
-
m
i
R
-
1
5
5
m
R
N
A
(
r
e
l
.
c
o
p
y
n
u
m
b
e
r
)
0.0001
0.001
0.01
0.1
BRetrovirology 2008, 5:100 http://www.retrovirology.com/content/5/1/100
Page 4 of 12
(page number not for citation purposes)
ray data gleaned from Tesi cells, which strongly expressed
BIC in the presence of Tax (Gene Expression Omnibus
accession GSE10508, [37]).
Quantification of BIC transcripts in HTLV-infected cells by
qPCR indicated high but variable RNA levels (Fig. 1B).
Higher sensitivity allowed detection of pri-miR-155 tran-
scripts in ALL cell lines Jurkat, HuT-78 and Molt4, which
had been negative in normal RT-PCR, but even then tran-
script levels were very low (Fig. 1B, inset). Statistical anal-
ysis (Mann-Whitney U-test) revealed the increase of BIC/
pri-miR-155 in HTLV-/Tax-transformed cells to be signifi-
cant (p < 0.001).
A set of Treg-specific mature microRNAs is upregulated in 
HTLV-1-transformed lymphocytes
Because, ultimately, the processed product of a microRNA
gene exerts the gene's functions, levels of mature miR-21,
miR-24, miR-146a, miR-155, miR-191, miR-214 and
miR-223 were determined by qPCR (Fig. 2). This
employed a specific stem-loop primer for reverse tran-
scription which also elongated the miR reverse transcript
to a length suitable for Taqman-based detection. Expres-
sion values were normalized to those of U6 small nuclear
RNA (snRNA). The assay revealed high amounts of miR-
155 in all HTLV-/Tax-positive cells with a mean relative
copy number of 586 and, moreover, these expression lev-
els were much higher than in HTLV-/Tax-negative con-
trols, which had a mean value of only 41 (Fig. 2). The
more than 14-fold difference turned out to be statistically
highly significant (p &#x226A; 0.0005). In summary, the
observed upregulation of BIC/miR-155 suggests a benefit
for HTLV-1 at some stage during its pathogenesis, i.e. miR-
155 might be involved therein.
To complete the analysis of oncogenesis-related microR-
NAs, miR-21, miR-24, miR-146a, miR-191, miR-214 and
miR-223 levels were determined in the same RNA samples
used for miR-155 detection. The expression of miR-191
and miR-214 did not differ between HTLV-/Tax-positive
and -negative cells (p > 0.4 in both cases). Both showed
only a moderate (miR-191) to low (miR-214) amount of
mature product. When analyzing miR-223, an outlier
value derived from one PBMC sample, which was more
than 60 times higher than the mean of the rest of the val-
ues, biased expression in HTLV-negative samples towards
a higher mean. However, even when ignoring that outlier,
HTLV-negative cells expressed significantly more miR-223
than HTLV-positive ones (p  ≈ 0.01). Quantitative PCR
revealed high expression of miRs 21, 24 and 146a in
HTLV-/Tax-positive cells with mean values of 689, 200
and 335, respectively. In all three instances, expression
significantly exceeded that of HTLV-negative controls. For
all HTLV-1 positive cell lines the number of proviruses per
cell was determined in qPCR analyses. A Spearman-Rho
test, however, did not turn up any significant correlation
between proviral load and microRNA expression level
(see additional file 1: Table S1, Correlation analysis of
provirus copy number and microRNA expression levels).
Taken together, these results describe a characteristic pat-
tern of oncogenesis-related microRNAs in HTLV-trans-
formed lymphocytes: miRs 21, 24, 146a and 155 are
upregulated, miR-223 is repressed and miRs 191 and 214
are unchanged compared to controls. The pattern, partic-
ulary the dysregulated microRNA species, might be rele-
vant to the growth and survival of the transformed cell or
might contribute to the process of transformation itself.
Expression of endogenous miR-146a is stimulated by 
HTLV-1 Tax
The observed overexpression of miRs 21, 24, 146a and
155 raised the question whether this was due to viral
interference. In particular, HTLV-1 Tax is a prime candi-
date for mediating such interference, but other viral pro-
teins (p30II, HBZ) known to have an impact on cellular
gene expression were also tested. We investigated the
effect of ectopically expressed viral proteins on endog-
enous microRNAs in Jurkat T cells by transfecting them
with expression plasmids for Tax, p30II and HBZ. After 48
hours, extracted RNA was assayed for the presence of
mature microRNAs 21, 24, 146a and 155. Among the four
microRNAs, one, miR-146a, was clearly upregulated in
the Tax-expressing cells (Fig. 3). The observed difference
with and without Tax was about 5-fold. Because suitable
antibodies were not available, expression of HTLV-1 pro-
teins p30II and HBZ could not be verified. Consequently,
the lack of an effect on endogenous miR-146a might also
be due to absence or too low expression levels of those
proteins. This also applies to the other microRNAs, which
were not significantly affected by any of the viral proteins
(data not shown).
MIRN146A promoter is transactivated by Tax via NF-κB
We tested the hypothesis that the upregulation of miR-
146a in the presence of Tax might happen through pro-
moter transactivation. A 558 bp genomic fragment
upstream of the miR-146a gene (MIRN146A) was cloned
into a luciferase reporter plasmid and cotransfected into
Jurkat T cells together with expression plasmids for viral
Tax or controls (Fig. 4A). The cloned sequence contained
two NF-κB binding sites starting at positions 68 bp and
386 bp (MatInspector analysis and [47]). Wildtype Tax
activated the promoter strongly (circa 15-fold) (Fig. 4B).
To find involved transcriptional pathways, Tax mutants
M7 (CREB-/NF-κB-), M22 (CREB+/NF-κB-) and M47
(CREB-/NF-κB+) were tested in the reporter assay. Because
M47 stimulated the promoter like wildtype Tax whereas
M22 had no effect, this suggested NF-κB-mediated trans-
activation. This conclusion was corroborated by cotrans-
fecting a dominant active inhibitor of NF-κB, IκBDN,Retrovirology 2008, 5:100 http://www.retrovirology.com/content/5/1/100
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OncomiRs are overexpressed in HTLV-transformed lymphocytes Figure 2
OncomiRs are overexpressed in HTLV-transformed lymphocytes. Expression levels of mature microRNAs miR-21, 
miR-24, miR-146a, miR-155, miR-191, miR-214 and miR-223 were detected by qPCR in two independent measurements. For 
each microRNA, samples from HTLV-/Tax-positive cell lines (blue) were compared to those of HTLV-/Tax-negative controls 
(black). U6 snRNA was used for normalization. Differences in the mean expression values were evaluated using the Mann-
Whitney U-test.
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which completely suppressed the effect of wildtype Tax.
Interestingly, deletion of the proximal NF-κB binding site
had the same effect (Fig. 3D), thus, indicating that this site
was sufficient for controlling the promoter. Loss of the
distal NF-κB site did not affect promoter activity nega-
tively (Fig. 3C). In short, HTLV-1 Tax specifically and
strongly activated the MIRN146A promoter via single NF-
κB site proximal to the transcription start. This explained
the elevated levels of mature miR-146a in HTLV-trans-
formed lymphocytes.
In silico analysis returns potential targets of collaborative 
microRNA effects
A bioinformatic approach to target genes could either
emphasize the impact of each miR separately or focus on
potential collaborative effects. Several online databases
for target gene predictions are available, like micro-
RNA.org [48], TargetScan [49], mirDB [50] and PicTar
[51], yet only the microRNA.org resource allowed screen-
ing for genes targeted by several microRNAs simultane-
ously. After selecting that option, the resulting output was
supplemented with predictions from the other databases
(Table 1). For more than half the target genes predicted by
microRNA.org, one or several binding sites for miRs 21,
24, 146a or 155 were predicted by other databases as well.
An analysis of gene ontology terms (GO terms, [52])
revealed that most of the annotated genes impinge upon
biological processes like signal transduction, regulation of
cell proliferation and transcription.
Importantly, the in silico analysis produced two genes
already associated with regulation by microRNAs-
Expression of endogenous miR-146a is stimulated by HTLV-1  Tax Figure 3
Expression of endogenous miR-146a is stimulated by 
HTLV-1 Tax. Jurkat T cells were transfected with expres-
sion plasmids for the HTLV-1 proteins Tax, p30II and HBZ or 
a control (pcDNA3). After 48 hours, RNA was extracted 
and subjected to qPCR detection of mature miR-146a. U6 
snRNA was used for normalization. Values represent the 
means of at least three independent experiments.
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SMAD5and TP53INP1. Both have been described to be
repressed by miR-155 [53,54]. TP53INP1 is a proapop-
totic protein involved in regulating p53-dependet cell
death [55,56], SMAD5 is critical to TGF-β-mediated inhi-
bition of proliferation in hematopoiesis [57]. Together
with the upregulated expression of miR-21, miR24, miR-
146a and miR-155, the conducted in silico analysis raises
the possibility that, besides miR-155, other miRs might be
involved in suppressing translation of SMAD5  or
TP53INP1 even further. Experiments to test this hypothe-
sis are currently ongoing. In summary, it might be worth-
while to re-examine genes which until now have only
been tested for regulation by a single microRNA instead of
the concerted effects of several.
Discussion
MicroRNAs have emerged as an important factor in post-
transcriptional regulation of gene expression with ties to
cellular processes such as proliferation and differentia-
tion. It has been demonstrated that microRNAs can con-
tribute to the deregulation of such processes [34].
Consequently, the use of microRNAs may help a virus to
attain e.g. persistence and, indeed, some viruses bring
their own microRNAs [30,31]. Lacking any self-encoded
microRNAs, HTLV could still interfere with host cell
microRNAs in order to drive it towards accelerated prolif-
eration and longevity.
This study approached HTLV-1's impact on cellular micro-
RNA expression, focussing on a defined subset of onco-
genesis-related specimens rather than relying on
undirected microarray screening techniques. The selection
procedure took into account (a) Treg-specific expression
patterns of microRNAs and (b) available functional char-
acterization, i.e., links to oncogenicity. While the patterns
were based on data gathered in mice, comparability was
maintained by phenotypically characterizing the cell lines
used in this study (data not shown). This ensured conti-
nuity with both the mouse data and published descrip-
tions of HTLV-transformed T cells' phenotype. Out of a
Table 1: Genes with predicted simultaneous seed matches for miR-21, miR-24, miR-146a and miR-155.
Gene Seed matches for miR Seed matches in other databases Gene ontology (GO) terms for biological processes
21 24 146a 155
SH3TC2 12 3 3 1 5 5 1 signal transduction
ITGB3 3 2 3 1 - cell adhesion
MMP16 21 2 3 2 4 1,2, 146a1, 1553 -
PURB 22 2 2 2 1 1,2, 241,2 regulation of myeloid cell differentiation
FAM130A1 11 3 2 1 5 5 3 positive regulation of transcription
SMAD5 2 1 3 1 - signal transduction (TGF-β)
ONECUT2 2 2 1 2 146a3 organ morphogenesis
DCX 1 2 1 2 - CNS development
EIF2C4 2 1 2 1 - chromatin silencing
CBFA2T2 1 2 1 2 - negative regulation of transcription
JHDM1D 31 1 1 2 1 3 -
SLC12A6 11 1 2 2 4 1,2,3, 1553 cell volume homeostasis
ZNF532 1 1 2 1 146a1 -
TP53INP1 21 1 1 2 4 1,2, 1551,2,3 -
KIAA1128 21 1 1 - -
CLCN5 22 1 1 2 4 1 excretion
FLJ25778 11 2 1 - -
CREBL2 11 1 2 2 1 1,2, 241,2, 146a3 signal transduction transcription
RFXDC2 11 1 2 1 4 6 a 1,3 -
YOD1 11 1 2 2 1 1, 241 amino acid metabolic process
VGLL3 21 2 1 2 4 3 -
PPM1D 1 1 1 2 - negative regulation of cell proliferation
CYBB 1 2 1 2 - innate immune response, inflammatory resp
RP11-93B10.1 11 1 1 2 4 3, 146a1,2, 1551 -
COL19A1 11 1 1 1 5 5 3 -
LOC348120 11 1 1 - -
AFF1 11 1 1 - t r a n s c r i p t i o n
RDX 11 1 1 - -
RIT1 11 1 1 2 1 1, 241, 155 signal transduction
USP31 11 1 1 - -
ARHGEF1 11 1 1 2 1 3 cell proliferation
SERTAD2 11 1 1 1 5 5 1 negative regulation of cell growth
In silico analysis (microRNA.org) of genes carrying at least one binding site for each of the four microRNAs. Results were compared to those 
obtained from other databases (TargetScan, PicTar, mirDB) and hits listed in column "Seed matches in other databases".
1TargetScan, 2PicTar, 3mirDBRetrovirology 2008, 5:100 http://www.retrovirology.com/content/5/1/100
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panel of seven microRNAs, four were highly and signifi-
cantly upregulated in HTLV-/Tax-positive samples as com-
pared to controls, namely miR-21, miR-24, miR-146a and
miR-155, whereas miR-223 was downregulated. The
remaining two microRNAs, miR-191 and miR-214, were
present in small amounts yet not regulated. Overall, the
emerging pattern of microRNA expression in HTLV-trans-
formed cells even within the investigated group of seven
miRs illustrates the validity of our selective approach.
Moreover, the pattern might contribute to a more detailed
phenotypic characterization of HTLV-transformed cells,
complementing well established protein markers. BIC
and its mature product, miR-155, can be regarded as a
prototypical oncomiR since it was first described as an
integration site for avian leukosis virus before being iden-
tified as capapble of cooperation with myc in cancerogen-
esis [43]. Moreover, miR-155 appears to be involved in
regulating a variety of lymphoid processes, particularly
differentiation [58]. The overexpression of miR-155 in
HTLV-transformed cell lines fits into that picture, hinting
at a possible involvement in the pathogenesis of HTLV-
associate disease at some point. Because the expression
level of the BIC primary transcripts mirrored – insomuch
as they were elevated – those of the mature miR-155, this
indicated that miR-155 expression is probably controlled
on a transcriptional level. Direct viral interference – in
particular one of HTLV-1 Tax – with BIC/miR-155 expres-
sion could not be detected. The differences seen in Tesi
cells, with and without Tax, could not be reproduced in an
independent system. Clarifying this issue probably would
have to take into account aspects of hematpoietic differen-
tiation. It is worth mentioning that, though the associa-
tion of hematologic malignancies with high miR-155
expression has been repeatedly described, no mechanism
for its upregulation has been presented. Involvement of
transcription factors AP-1 and NF-κB during normal
immune function of B cells has been described, however
[59,60].
While expression levels of miR-191 and miR-214 did not
significantly differ between HTLV-positive and -negative
samples, miR-223 was downregulated in an HTLV con-
text. The latter is particularly interesting since reduced
miR-223 abundance has been described recently in hepa-
tocellular carcinoma [61]. When overexpressed, miR-223
led to a decrease in cell viability by targeting stathmin.
According to this link between miR-223 and stathmin, the
observed downregulation of miR-223 in our study could
potentially be involved in HTLV-1 cell-to cell spread in
vivo [62,63].
Ectopically expressing HTLV-1 Tax in Jurkat T cells, which
express only low levels of miR-146a, entailed a marked
increase in miR-146a expression, thus, demonstrating that
Tax is able to boost the cellular signals underlying that
expression. Subsequent promoter analysis refined the ini-
tial observation, showing a circa 15-fold activation by Tax
and explained the observed high levels of miR-146a in
HTLV-transformed cell lines. Using mutated forms of Tax
and the coexpression of a dominant active NF-κB inhibi-
tor, we were able to pinpoint the transactivation as being
mediated via NF-κB. These findings are in line with data
by other groups who described NF-κB regulation of miR-
146a expression [47]. The previously published upregula-
tion of miR-146a expression by EBV LMP-1 is of interest
because it adds to the relevance of our findings [64,65].
Conceivably, this constitutes an important facet in both
viruses' efforts to establish perstistence or their potential
to bring about malignant transformation. In contrast to
activation by LMP-1, Tax uses only one of the two NF-κB
sites present in the promoter sequence proximal to the
transcriptional start site. Other transcription factors do
not seem to participate in the Tax effect since the deletion
of that aforementioned singular NF-κB site completely
abrogated promoter activity. Recent data by Bhaumik et
al. describe a suppressive effect of miR-146a on NF-κB sig-
naling [66]. This could constitute a negative feedback
loop of miR-146a on its own expression, which is ren-
dered inoperative in an HTLV context. Taken together, our
studies indicate that miR-146a stimulation in HTLV-trans-
formed cells can be traced back to promoter transactiva-
tion by HTLV-1 Tax via NF-κB.
Defining target genes for microRNAs bioinformatically is
difficult owing to inherent inaccuracies in predictive algo-
rithms, because, unlike siRNAs, microRNAs do not
depend on perfect sequence complementarity to targets.
Nevertheless, some targets have been described, like
IRAK6 and TRAF1 3'-UTRs for miR-146a [47]. Another
study [65] found endogenous IRAK6 and TRAF1 mRNA
levels to be not or barely (respectively) miR-146a-regu-
lated which could hint at the involvement of further regu-
latory elements, like additional microRNAs. Looking at
cooperative effects of several microRNAs on a given
mRNA might help avoiding such conflicting data. Inter-
estingly, two targets ascribed to miR-155, SMAD5 [53]
and TP53INP1 [54], came up in our analysis as having
predicted binding sites for all four upregulated micro-
RANs, miR-21, miR-24, miR-146a and miR-155. In the
latter case, this was bolstered by congruent predictions
from different databases. An upcoming paper describes
that TP53INP1 is targeted by miRs 93 and 130b which
were found to be overexpressed in both samples from
patients suffering from acute ATLL and ATLL-derived cell
lines [67]. The same paper also mentions the upregulation
of miR-155 in ATLL patient samples. This strengthens our
point that microRNAs do play a role in the pathogenesis
of HTLV-associated disease. With regard to our findings,
the data from Yeung at al. open up the possibility that a
combined 'attack' of miR-155, miR-93, miR130b and
maybe one the microRNAs investigated in this study on
TP53INP1  might even increase documented microRNARetrovirology 2008, 5:100 http://www.retrovirology.com/content/5/1/100
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effects on its mRNA. In summary, a combinatorial
approach to the search for microRNA targets might help
finding new targets or refining the regulation of known
ones.
Conclusion
This study analyzed the impact of HTLV-1 on cellular
microRNAs. Filtering microRNAs for phenotypic restric-
tion and oncogenesis-relatedness produced a set of seven
microRNAs out of which four (miR-21, miR-24, miR-
146a and miR-155) were overexpressed in HTLV-trans-
formed cells. MicroRNA miR-223, however, was signifi-
cantly repressed in an HTLV context. The validity of our
approach is illustrated by the fact that it delivered miR-
155, which appears to be a key player in lymphocyte
malignancies, and miR-146a, whose upregulation has
also been described in an EBV context [64,65]. The latter
suggests this to be a more common phenomenon in the
pathogenesis of persistent viruses, which should be
inspected more closely. Moreover, taking into account
possible collaborative effects of microRNAs when looking
for target genes might reveal targets whose regulation is
easily missed when testing a single microRNA or might
refine our knowledge about regulation of known targets.
Methods
Cell culture
HTLV-1-negative acute lymphoblastic leukemia (ALL) T
cell lines Jurkat, HuT-78, and CEM (CCRF-CEM), the
ATLL patient-derived HTLV-1-positive T cell lines HuT-
102, StEd, ATL-3, PaBe, JuanaW, Champ, and the HTLV-1
in vitro-immortalized, interleukin-2 (IL-2)-independent T
cell lines C91-PL and MT-2 were kept as described [37].
The HAM/TSP patient-derived HTLV-1-positive T cell lines
Abgho, Nilu (both 40 U/mL IL-2), Eva and Xpos (both 20
U/mL IL-2) were cultured in RPMI 1640 containing 40%
Panserin (PAN-Biotech, Aidenbach, Germany), 20% fetal
calf serum (FCS), glutamine (0.35 g/L), streptomycin and
IL-2 (Roche Diagnostics, Mannheim, Germany) as indi-
cated. The cell line Tesi was cultured as described [37].
Tesi is a Tax in vitro-immortalized T cell line featuring tet-
racycline-repressible Tax expression [18]; for complete Tax
repression, cells were grown in medium containing 1 μg/
mL tetracycline for ten days. In order to stimulate CEM
cells, 0.1 μg/mL phorbolmyristate actetate (Sigma, Ham-
burg, Germany) and 2 μM ionomycine (Calbiochem, San
Diego, CA) were added to the medium for 18 hours.
Isolation of PBMC and lymphocyte populations
Peripheral blood mononuclear cells (PBMC) were iso-
lated from buffy coats from health donors (Institute of
Transfusion Medicine, Suhl, Germany) by Ficoll density
gradient (Biocoll, Biochrom, Berlin, Germany). CD4+ and
CD4+CD25+ T cell subsets were separated from PBMC
using the Regulatory T Cell Isolation kit (Miltenyi Biotech,
Bergisch-Gladbach, Germany) and subjected to RNA
extraction immediately afterwards.
MicroRNA primary transcript and mRNA detection
Total cellular RNA from cell lines and PBMCs was isolated
(Trizol, Invitrogen, Karlsruhe, Germany) and reversely
transcribed (Superscript II, Invitrogen) using random hex-
amer primers (Invitrogen). Primers and probes are listed
in additional file 2 (Table S2, Primers and probes). Quan-
titative real-time RT-PCR (qPCR) was performed on an
ABI Prism 7700 Sequence Analyzer (Applied Biosystems,
Foster City, CA) from 200 ng cDNA. In RT-PCR, 500 ng
cDNA were used as template. Expression levels were com-
puted by interpolation from standard curves generated
from plasmids and calculating the mean of triplicate sam-
ples. β-actin (ACTB) was used for normalization.
Quantification of mature microRNAs
Quantification of mature microRNAs was performed
using TaqMan MicroRNA Assays (Applied Biosystems,
Darmstadt, Germany) according to the manufacturer's
protocol. Reverse transcription (RT) employed the Micro-
RNA Reverse Transcription Kit (Applied Biosystems,
Darmstadt, Germany). Mature microRNAs were reversely
transcribed using specific stem-loop primers which allow
for generation of cDNA and, at the same time, elongation
of the transcript up to a length amenable to analysis by
qPCR. Input was 10 ng of total cellular RNA per RT reac-
tion. After real time qPCR, expression values were normal-
ized to that of U6 small nuclear RNA (RNU6B). For all of
the HTLV-/Tax-positive cell lines as well as the PBMC,
CD4 and one series of CEM (stim) cells, RNU44 tran-
scripts were analyzed in parallel as an alternative normal-
ization control. A comparison of U6, U44 and the
geometric mean of both as normalization controls for
microRNA expression is given in additional file 3 (Figure
S3, Quantification and comparison of U44 expression in
HTLV-1-/Tax-positive and -negative cells) and additional
file 4 (Table S4, MicroRNA expression normalized to U6,
U44 or U6/U44 geometric mean). Standard curves were
generated using DNA oligos with sequences identical to
those of the mature microRNAs. The quantification was
conducted in two independent measurement series, each
of which comprised separate RNA extraction, reverse tran-
scription and subsequent qPCR.
Determination of provirus copy numbers
Proviral copy numbers were determined according to
Dehee et al. [68]. Briefly, genomic DNA was extracted
from cells using Trizol (Invitrogen) and 100 ng were used
per qPCR reaction. In contrast to [68], the total volume
reaction volume was 20 μL each and the annealing/exten-
sion cycle was one minute at 60 degrees celsius. Primers
SK110 and SK111, which are located in the pol region of
the HTLV-1 genome, detected provirus copies. ValuesRetrovirology 2008, 5:100 http://www.retrovirology.com/content/5/1/100
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were normalized to copies of the human albumin gene
(ALB), of which two alleles per cells are present. Standard
curves were generated from a plasmid, pcHTLV-ALB, car-
rying both relevant target sequences of the qPCR.
Analysis of effects of HTLV-1 proteins on endogenous 
microRNAs
Jurkat T cells were transfected by electroporation with
expression plasmids for HTLV-1 Tax, p30II [69] or HBZ
[13]. After 48 hours, RNA was extracted and the level of
microRNAs determined as described in section 'Quantifi-
cation of mature microRNAs'.
Promoter analysis
A 558 bp fragment of genomic DNA [Genbank:
NT_023133.12 Hs5_23289: 4704215-4704772]
upstream of the MIRNA146A (miR-146a) gene, located
on chromosome 5q33.3, was cloned into pGL3basic
(Promega, Mannheim, Germany) using Pwo polymerase
(Roche Diagnostics) and primers containing NheI and
HindIII restriction sites producing
pGL3basic:miR146aprom. The NF-κB deletion mutants
pGL3basic:miR146aΔNF-κBdist and
pGL3basic:miR146aΔNF-κBprox were generated by over-
lap-extension PCR. All plasmids were sequenced. Tax
impact on the miR-146a promoter was tested in reporter
gene assays in transfected Jurkat T cells as described [37].
Briefly, Jurkat T cells were cotransfected by electropora-
tion (EasyJect plus, Equibio, Ashford, United Kingdom, at
290 V and 1500 μF) with 20 μg of the reporter construct
and either 20 μg pcDNA3, pcTax [70], pM7, pM22, pM47
[71] or 2 μg pIκBDN [72]. Luciferase activity was meas-
ured after 48 hours (Orion Microplate Luminometer;
Berthold, Pforzheim, Germany) and normalized to pro-
tein concentration. Each combination was tested at least
three times. Values are given as multiple of the control
(pGL3basic:miR-146aprom plus pcDNA3).
Statistical analysis
For evaluation of differences in expression levels of HTLV-
1-/Tax-positive and -negative samples, the Mann-Whitney
U-test was applied using SPSS version 12.0.2 (SPSS, Chi-
cago, IL). Stimulated CEM cells were excluded from the
calculation. Analysis of correlations between provirus
copy number and microRNA expression employed the
Spearman-Rho test.
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